Results 151 to 160 of about 5,019 (231)

Redefining the Role of Chemotherapy and Targeted Cytotoxic Delivery in Lung Neuroendocrine Tumors

Thoracic Cancer, Volume 17, Issue 16, August 2026.
Perioperative chemotherapy utility remains uncertain and lacks universal standardization. Platinum/etoposide shows suboptimal efficacy in lung NET (neuroendocrine tumors); oral alkylators (temozolomide) alone or in combination (e.g., with capecitabine), and cabozantinib offer promising disease control.
Alice Laffi, Giuseppe Lamberti, Anna La Salvia   +2 more
wiley   +1 more source

Targeting IL13Rα2 in melanoma with a bispecific T-cell engager: expression profiling and preclinical evaluation. [PDF]

J Immunother Cancer
Zhao S, Chen Y, Bhojnagarwala PS, Livingston C, Jose J, Gao Y, Park DH, Herlyn M, Weiner DB.   +8 more
europepmc   +1 more source

Clinical and immunological effects of adding cyclophosphamide to pomalidomide–dexamethasone in relapsed‐refractory multiple myeloma: The randomized MUKseven trial

British Journal of Haematology, Volume 209, Issue 2, Page 557-568, August 2026.
Summary There is an ongoing need for accessible combination therapies for patients with relapsed‐refractory multiple myeloma (RRMM), alongside a growing interest in understanding their immunological effects, particularly on T‐cell populations. Myeloma UK (MUK) MUKseven (NCT02406222) was an academic, UK multicentre randomized controlled, open‐label ...
Andrew Hall, James Croft, Katrina Walker, Kevin Boyd, Sadie Roberts, Amy Holroyd, Mamta Garg, Elsa Ferris, Gordon Cook, William E. Pierceall, Anjan Thakurta, Anita Gandhi, Charlotte Pawlyn, Sarah R. Brown, Martin Kaiser   +14 more
wiley   +1 more source

A measles virus encoding a CD19/CD3 bispecific T cell engager shows enhanced preclinical anti-BCP-ALL efficacy without significant toxicity. [PDF]

Mol Ther Oncol
Heinze S, Stadler GL, Zhang Y, Engeland CE, Barth TFE, Heidbuechel JPW, Meyer LH, Mühlebach MD, Debatin KM, Dorneburg C, Beltinger C.   +10 more
europepmc   +1 more source

Anti‐BCMA immunotherapies deplete plasmacytoid dendritic cells and impair antiviral immunity in multiple myeloma

HemaSphere, Volume 10, Issue 8, August 2026.
Ondrej Venglar, Eva Radova, Maxima Warmuzova, Daniel Bilek, Marketa Kudelkova, Katerina Jasinkova, Ludmila Muronova, Lucie Broskevicova, Veronika Kapustova, Jan Vrana, Tereza Novakova, Katerina Karasova, Michaela Hornakova, Tereza Popkova, Jana Mihalyova, Hana Plonkova, Michal Simicek, Jakub Radocha, Tereza Sevcikova, David Zihala, Juli Bago, Roman Hajek, Tomas Jelinek   +22 more
wiley   +1 more source

Multivalent antibody‐based conjugates as new tools for tailored modulation of G protein–coupled receptors

British Journal of Pharmacology, Volume 183, Issue 16, Page 4512-4531, August 2026.
The G protein–coupled receptor (GPCR) superfamily consists of the most common targets of approved drugs. Targeting GPCRs offers appealing avenues for therapeutic development. Antibodies and their fragments, such as single‐domain antibodies (VHHs or nanobodies), have emerged as useful alternatives to small molecule pharmacophores as building blocks in ...
Shivani Sachdev, Ross W. Cheloha
wiley   +1 more source

Virus envelope glycoprotein targeting bispecific T cell engager protects mice from lethal severe fever with thrombocytopenia virus infection. [PDF]

Cell Rep Med
Peng X, Wang W, Liang Y, Jian Y, Wei Q, Yang T, Wang C, Yin X, Du M, Shang H, Liu R, Wang X, Shang X, Gong N, Xu Y, Wang C, Cui N, Zhang L, Guo Y, Liu W, Zhang H, Li H.   +21 more
europepmc   +1 more source

Minimal Residual Disease as a Biological Trait: Rethinking Disease Persistence in Hematologic Malignancies

European Journal of Haematology, Volume 117, Issue 2, Page 320-337, August 2026.
ABSTRACT Minimal residual disease (MRD) has emerged as a central biomarker in hematologic malignancies, enabling highly sensitive detection of tumor persistence beyond conventional morphologic assessment and serving as an increasingly important surrogate endpoint in clinical trials.
Santino Caserta, Enrica Antonia Martino, Ernesto Vigna, Mamdouh Skafi, Antonella Bruzzese, Nicola Amodio, Eugenio Lucia, Graziella D'Arrigo, Virginia Olivito, Caterina Labanca, Francesco Mendicino, Maria Eugenia Alvaro, Giovanni Tripepi, Fortunato Morabito, Massimo Gentile   +14 more
wiley   +1 more source

Solution structure and synaptic analyses reveal determinants of bispecific T cell engager potency. [PDF]

Proc Natl Acad Sci U S A
Leithner A, Staufer O, Mitra T, Liberta F, Valvo S, Kutuzov M, Dada H, Spaeth J, Zhou W, Schiele F, Reindl S, Nar H, Hoerer S, Crames M, Comeau S, Young D, Low S, Jenkins E, Davis SJ, Klenerman D, Nixon A, Pefaur N, Wyatt D, Dushek O, Kasturirangan S, Dustin ML.   +25 more
europepmc   +1 more source

Emerging Immune‐Based Therapeutic Strategies in Hepatocellular Carcinoma

Liver International, Volume 46, Issue 8, August 2026.
ABSTRACT Hepatocellular carcinoma (HCC) remains a leading cause of cancer‐related mortality worldwide despite recent advances in systemic therapy. The introduction of immune checkpoint inhibitors has substantially expanded treatment options for advanced disease; however, durable responses are observed only in a subset of patients.
Janine Kah, Werner Dammermann, Stefan Lueth   +2 more
wiley   +1 more source